NC woman legislator, activists p…

  Srinagar:Women workers…

TN CM invites Modi for Jaya, MGR…

  New Delhi: Tamil Nadu …

Twitter launches customisable Di…

  New Delhi: Twitter on …

Miniature artist presents hyperr…

New Delhi: In an attemp…

Gloom in Indore over death of 24…

  Indore: A pall of gloo…

In Arunachal, tribal taboos are …

"My Naba (father) alway…

HC notice to Kejriwal on Jaitley…

  New Delhi: The Delhi H…

Army to assist in disposal of ol…

  New Delhi: After assis…

Ex-RJD MP gets life term in murd…

  Ranchi: Former RJD MP …

ED arrests CA of Lalu's daughter…

  New Delhi: The Enforce…

«
»
TwitterFacebookPinterestGoogle+

The BD FACSPresto system has expanded the ability to stage and monitor HIV/AIDS patients close to their homes

Facebooktwittergoogle_plusredditpinterestlinkedinmail

BD (Becton, Dickinson and Company), a leading global medical technology company that emphasizes on point of care services and devices, presents it BD FACSPresto™. This CD4 patient monitoring system provides absolute and percentage results of CD4 T lymphocytes and hemoglobin (Hb) concentration in whole blood samples. Weighing less than 7kgs, BD FACSPresto™ is capable of testing samples from a single drop of capillary or venous blood and can work for 6 hours using in-built rechargeable battery, enabling testing even in remote settings.

CD4 testing allows HIV/AIDS patients to have access to treatment and monitoring, reducing the probability of transmitting the infection to others and providing a plan for improved long-term care. Immediate treatment for infected individuals who meet medical guidelines can dramatically quell the spread of HIV according to the World Health Organization (WHO). This is particularly important as many new cases of HIV/AIDS are transmitted from people who are not aware they are infected.

“The BD FACSPresto system has expanded the ability to stage and monitor HIV/AIDS patients close to their homes,” said Varun Khanna, Managing Director, BD India. “This system has meet the needs of resource-limited settings in high prevalence states like Andhra Pradesh, Maharashtra, Tamil Nadu, Karnataka and North East states without compromising the standards of precision and assuring operators and patients a high degree of confidence in results,” he said.

Leave a Reply

Your email address will not be published. Required fields are marked *

CAPTCHA Image

*